New vaccine aims to boost immunity against advanced cervical cancer

NCT ID NCT06315257

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 19 times

Summary

This early-stage trial tests a new vaccine called PVX7 in 32 women with advanced cervical cancer who have finished their main treatment (surgery, radiation, or chemo). The goal is to see if the vaccine is safe and can boost the body's immune response against HPV, the virus that causes cervical cancer. Participants will receive three doses of the vaccine, and researchers will monitor side effects and immune system activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35233, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.